Cansino Biologics Inc., commonly referred to as Cansino, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2009, the company has established itself as a leader in the development of innovative vaccines and biologics, with a strong focus on addressing global health challenges. Cansino operates primarily in the fields of vaccine research and development, particularly in the areas of infectious diseases and oncology. The company gained significant recognition for its pioneering work on the Ad5-nCoV vaccine, which was one of the first COVID-19 vaccines to receive emergency use authorisation. Cansino's unique adenoviral vector platform sets it apart in the industry, enabling rapid development and deployment of vaccines. With a robust pipeline and strategic partnerships, Cansino Biologics continues to solidify its position as a key player in the global biopharmaceutical landscape.
How does Cansino Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cansino Biologics's score of 37 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Cansino Biologics reported total carbon emissions of approximately 37,294,900 kg CO2e, comprising Scope 1 emissions of about 3,000,700 kg CO2e and Scope 2 emissions of approximately 14,064,580 kg CO2e. Additionally, Scope 3 emissions, primarily from fuel and energy-related activities, reached about 19,689,150 kg CO2e. This data indicates a significant carbon footprint, reflecting the company's extensive operational activities. Cansino Biologics has set ambitious reduction targets, aiming for a 40% reduction in total greenhouse gas emissions per floor area by 2025, using 2021 as the baseline year. Furthermore, the company plans to achieve a 50% reduction by 2030 for both Scope 1 and Scope 2 emissions. These commitments demonstrate Cansino's proactive approach to addressing climate change and reducing its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Scope 1 | 4,609,750 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 10,386,950 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 |
Scope 3 | - | - | - | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cansino Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.